drugset / Trial / NCT01143948

Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial

NCT01143948

Phase 4 Unknown 45 enrolled Cairo University Sanofi · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Liver disease is an important cause of death in type 2 diabetes. In the population-based Verona Diabetes Study cirrhosis was the fourth leading cause of death and accounted for 4.4% of diabetes-related deaths. In another prospective cohort study , cirrhosis accounted for 12.5% of deaths in patients with diabetes. In Egypt hepatitis C virus the commonest of cirrhosis here has a prevalence of 9.8% in the population with the greatest burden over national health care bills. Patients with cirrhosis \& type 2 diabetes mellitus are always showing up in all hospital wards without a clear consensus of best management of their hyperglycemia.

Timeline

Start
2011-01
Primary completion
2011-04
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Protein / enzyme biologic
Comparator Insulin glulisine Protein / enzyme biologic
Comparator NPH Unknown
Comparator insulin glargine Protein / enzyme biologic